NYSE:DVA   DaVita Inc.
Corporate Profile
DaVita is a Fortune 500® health care provider focused on transforming care delivery to improve quality of life for patients around the globe. The company is the largest provider of kidney care services in the U.S. and has been a leader in clinical quality and innovation for 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage renal disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. As of June 30, 2020, DaVita served 205,000 patients at 2,795 outpatient dialysis centers in the United States. The company also operated 287 outpatient dialysis centers in ten countries across the world. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere.

There are like 5 of these within every mile in Chicago lol

It's inevitable lol

*not investing advice

Today, DaVita Kidney Care announced that more than 100,000 DaVita patients have received a kidney transplant since 2000. This milestone represents the culmination of two decades of innovative strategies spearheaded by the kidney care provider to increase patient education and access to kidney transplantation.

DaVita Kidney Care (PRNewsfoto/DaVita Kidney Care)

"We are deeply committed to helping every interested patient be evaluated by transplant centers and stay transplant ready," said Dr. Jeff Giullian, chief medical officer for DaVita. "Transplant is the best option for most patients with kidney failure, as it's the only way for these patients to live without relying on dialysis."

According to the United Network for Organ Sharing (UNOS), 24,273 people received a kidney transplant in the United States in 2019. More than 6,000 DaVita patients have already received a transplant in 2020, despite the many setbacks transplant programs faced due to COVID-19.

At the same time, nearly 100,000 people in the United States remain on a kidney transplant waitlist. The average wait for a non-living kidney donor match is 3.6 years.

The Advancing American Kidney Health initiative launched in 2019 calls for doubling the number of kidneys available for transplant by 2030. The initiative lays out a roadmap to help organ procurement organizations and transplant centers reach this goal, which aligns with DaVita's longstanding work to empower all patients to choose to be evaluated for transplant.

My name is Ski Mask and I've been making bad decision all my life.

Strike Price: $109.35

Like Follow Agree Disagree!

What do you think?
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.